Clinical Trial Update: ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) [Phase 2]

View source ↗

Summary

A Phase 2 trial ARMOR evaluating renal mechanisms of creatinine excretion in patients with Type 2 diabetes treated with tesaglitazar has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: TERMINATED